<?xml version="1.0" encoding="UTF-8"?>
<p>Traditionally CD8 T-cells are associated with protection from viral infections via a combination of antiviral activities, including cytotoxicity and the release of pro-inflammatory and anti-viral cytokines, which can be enhanced by CD4 T-cells [
 <xref rid="B105-vaccines-07-00203" ref-type="bibr">105</xref>,
 <xref rid="B124-vaccines-07-00203" ref-type="bibr">124</xref>,
 <xref rid="B125-vaccines-07-00203" ref-type="bibr">125</xref>,
 <xref rid="B126-vaccines-07-00203" ref-type="bibr">126</xref>]. However, in dengue, CD8 T-cells have historically been associated with severe disease and capillary leakage, and many refer to Juthathip Mongkolsapaya [
 <xref rid="B127-vaccines-07-00203" ref-type="bibr">127</xref>] on this. The only early evidence really excluding a role for CD8s in severe disease was the discovery that maternal antibodies in infants without a pre-existing T-cell response was associated with increased severity [
 <xref rid="B62-vaccines-07-00203" ref-type="bibr">62</xref>]. Only recently has there been a considerable increase in evidence for a non-pathogenic or protective role of CD8 T-cells in dengue infection [
 <xref rid="B78-vaccines-07-00203" ref-type="bibr">78</xref>,
 <xref rid="B106-vaccines-07-00203" ref-type="bibr">106</xref>,
 <xref rid="B128-vaccines-07-00203" ref-type="bibr">128</xref>,
 <xref rid="B129-vaccines-07-00203" ref-type="bibr">129</xref>,
 <xref rid="B130-vaccines-07-00203" ref-type="bibr">130</xref>,
 <xref rid="B131-vaccines-07-00203" ref-type="bibr">131</xref>].
</p>
